Search the Newsreel

Viatris Inc. stock falls Friday, underperforms market

Viatris Inc. (VTRS) stock fell 1.13% on Friday, closing at $17.56, despite an overall positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for Viatris …

TriSalus Life Sciences (TLSI) Stock Forum and Discussion

This article provides a discussion forum for TriSalus Life Sciences (TLSI) stock. It encourages investors to share insights, analysis, news, and opinions to foster a community around the company's financial performance and future prospects. The forum aims to be a resource for informed decision-making …

Price to earnings forward of TriSalus Life Sciences, Inc. – BOATS:TLSIW

The article focuses on the "Price to earnings forward" metric for TriSalus Life Sciences, Inc. (BOATS:TLSIW), a company listed on the Blue Ocean Alternative Trade System. It appears to be a financial data page from TradingView, providing an overview of the company's financials without …

Trisura Announces Timing of Second Quarter Results Release and Earnings Conference Call

TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurer, announces the timing of second quarter 2026 results and earnings conference call. Trisura will release its second quarter 2026 results after market close on …

Viatris (VTRS) Q2 Earnings Preview: What's in the Cards?

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Viatris (VTRS) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its …

TriSalus Life Sciences Inc (TLSI) Financial Health: Profitability & Balance Sheet Analysis

TriSalus Life Sciences Inc (TLSI) has a financial score of 6.94, ranking 177th out of 384 in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company's latest quarterly revenue was $8.90M, a 2.92% year-over-year decrease, with net …

What Viatris (VTRS)'s FDA Approval of Weekly Gwyn Lo Contraceptive Patch Means For Shareholders

Viatris (VTRS) recently received FDA approval for Gwyn Lo, a new weekly low-estrogen contraceptive patch, which is expected to diversify its product mix towards higher-margin, branded offerings. This approval supports the company's strategy to shift from a generics-heavy portfolio to more complex and branded …

TriSalus Life Sciences (TLSI) to Post Earnings on Thursday

Vantris Energy Berhad Announces Retirement of Wan Mashitah Binti Wan Abdullah Sani as Independent and Non Executive Director, Effective July 30, 2026

Viatris Inc (VTRS) Risk Assessment: Volatility, Financial Risk & Investment Risk

Viatris Inc (VTRS) has a current risk assessment score of 8.80, placing it 21st out of 155 in the Pharmaceuticals industry. The company's beta of 0.89 indicates it tends to underperform during market uptrends but experiences smaller declines during downturns. The report details various …

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

TriSalus Life Sciences announced that its CEO and CFO will participate in the Canaccord Genuity 46th Annual Growth Conference, including one-on-one meetings and a fireside chat. The company focuses on oncology, integrating novel drug delivery technology with standard-of-care therapies for solid tumors, utilizing its …

Tristate Holdings Limited Revenue Breakdown – HKEX:458

TriSalus CEO and CFO to Join Canaccord Fireside Chat Aug. 12

TriSalus Life Sciences announced that its CEO and President, Mary Szela, and CFO, David Patience, will participate in the Canaccord Genuity 46th Annual Growth Conference. They will engage in one-on-one meetings on August 11-12 and a fireside chat on August 12 at 8:30 a.m. …

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. announced that the U.S. FDA has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen patch is indicated for women of childbearing potential with a BMI below 30 kg/m² and demonstrated efficacy and a well-characterized safety profile in …

TriSalus Life Sciences Inc (TLSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of TriSalus Life Sciences Inc (TLSI), focusing on its price momentum, support and resistance levels, and various technical indicators. It details the stock's current momentum score within the Biotechnology & Medical Research industry and offers insights from indicators …

Viatris Number of Employees 2026 | Employee Count & Headcount Data

Viatris, Inc. (NASDAQ: VTRS) reported approximately 29,935 global employees as of March 2026, marking a 3.8% decline from 2023. The company is actively hiring with 474 open job postings in 2026, a 10.7% increase from 2025. Viatris's workforce is primarily located in India (43.1%), …

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with …

Viatris Inc. stock rises Tuesday, outperforms market

Viatris Inc. (VTRS) stock rose 1.28% on Tuesday, closing at $17.86. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw gains. The increase marks the second consecutive day of gains for Viatris stock.

Is Tristel (LSE:TSTL) Exposed To The Latest UK Retail Reset?

Viatris Inc (VTRS) Income Statement

This article provides the quarterly and annual income statements for Viatris Inc (VTRS), offering detailed financial data such as total revenue, cost of revenue, operating expenses, operating profit, net income, and earnings per share (EPS). It includes year-over-year percentage changes and absolute figures across …

Viatris Inc (VTRS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Viatris Inc.'s (VTRS) shareholder structure, listing major shareholders and their proportionate holdings, along with institutional ownership trends over recent quarters. It also categorizes shareholders by type and lists ETFs with significant VTRS holdings.

Viatris stock hits 52-week high at $17.68

Viatris Inc. (VTRS) stock reached a 52-week high of $17.68, reflecting strong market performance with a 90.82% surge over the past year and a 2.78% dividend yield. The pharmaceutical company is considered undervalued by InvestingPro, with recent positive news including exceeding Q1 2026 financial …

TriSalus Life Sciences Inc (TLSI) Cash Flow

This article provides a comprehensive overview of TriSalus Life Sciences Inc.'s (TLSI) cash flow statements, including operating, investing, and financing activities, spanning multiple quarters and years. It details various financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year …

Trisura Group (TSX:TSU) Gains Attention Following Mixed Brokerage Updates

Viatris, Inc. Revenue Breakdown – BX:VTRS

Viatris, Inc. (VTRS) generated 11.34 billion CHF last year, with its "Brands" segment contributing the most at 7.28 billion CHF. The company's largest revenue contribution came from Developed Markets, accounting for 4.37 billion CHF. This data provides a snapshot of Viatris's key revenue drivers …

TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050

TriSalus Life Sciences Inc. (TLSI) is an oncology-focused medical technology company with a stock price of $4.22, down 1.17%. The company exhibits high growth potential and healthy fundamentals, with analysts largely rating it as a "Buy" with a target price of $9.00. Its platform …

TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI

This article provides a revenue breakdown for TriSalus Life Sciences, Inc. (NASDAQ: TLSI). Last year, the company generated $45.15 million USD, with its top-performing segment, Innovative Drug Delivery Technology and Immune-oncology Therapeutic, contributing the entirety of this amount. The United States was the sole …

PFE5003244 Bond Risk Profile

This article provides a risk profile for the PFE5003244 bond issued by Viatris Inc., maturing on June 22, 2030, with a 2.7% coupon rate. It focuses on key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors …

PFE5282056 Bond Profile — Key Metrics

This article provides a detailed profile of the PFE5282056 bond issued by Viatris, Inc. Key metrics include its 2.7% coupon rate, maturity date of June 22, 2030, and an outstanding amount of $1.45 billion. The piece also gives an overview of Viatris Inc., describing …

Viatris Inc. stock rises Thursday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.59% to $17.28 on Thursday, outperforming the broader market which saw the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) decline. The company's stock closed 2.23% below its 52-week high of $17.68. This rise occurred during …

Viatris, Inc. (VIA) Q2 2023 Earnings Report - Results, Call & Slides

Viatris, Inc. (VIA) reported its Q2 2023 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of €0.66 against a consensus of €0.62, and actual revenue of €3.43 billion against an expected €3.38 billion. The report includes details from the …

TriSalus Life Sciences Initiates PREDICTT Clinical Trial

TriSalus Life Sciences has commenced patient enrollment for the PREDICTT clinical trial, evaluating its Pressure-Enabled Drug Delivery (PEDD) approach for liver tumors. The study, conducted at The University of Texas MD Anderson Cancer Center, aims to optimize the delivery of Y90 radioembolization therapy using …

Viatris’ Quarterly Earnings Preview: What You Need to Know

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global healthcare company that develops, manufactures, and markets branded medicines, generic drugs, complex generics, biosimilars, and over-the-counter products. Valued at a market cap of $19.8 billion, Viatris …

Tristel delivers double-digit revenue growth as cash position strengthens ahead of CEO transition (LSE:TSTL)

PFE5003244 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the PFE5003244 bond issued by Viatris Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 2.70%, with the next payment expected on December 22, 2026. The article highlights how to …

Lobbying Update: $90,000 of TRISALUS LIFE SCIENCES lobbying was just disclosed

TRISALUS LIFE SCIENCES recently disclosed $90,000 in lobbying expenditures for Q2 2026, focusing on "Medicare and Medicaid reimbursement issues." This update also details significant insider trading activity for TLSI stock, with 26 transactions in the past 6 months showing more sales than purchases, and …